
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings is in a strong position as a commercial-stage biotechnology company with a diverse pipeline and a promising lead product, KIMMTRAK, for the treatment of unresectable or metastatic uveal melanoma (mUM). The company's robust post-progression survival data and favorable safety profile support its continued growth and potential expansion into new therapeutic areas. Additionally, the company's late-stage readouts in oncology, infectious disease, and autoimmune pipelines, as well as its focus on expanding its patient population and revenue growth, make it a promising investment opportunity with potential for upside in the future.
Bears say
Immunocore Holdings is a biotechnology company facing risks related to its diverse pipeline and potential challenges in obtaining regulatory approvals for its drugs. The company's financials may also be impacted by the need for additional funds to support clinical trials and commercialization efforts. With a low probability of success for its lead products, there is a significant downside risk for investors in the short term.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares